share_log

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals-Johnson & Johnson(10.7%),Johnson & Johnson Innovation-JJDC, Inc.(10.7%)

Johnson & Johnson | SC 13G: Statement of acquisition of beneficial ownership by individuals

強生 | SC 13G：超過5%持股股東披露文件
美股sec公告 ·  04/10 17:17
Moomoo AI 已提取核心訊息
Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on April 10, 2024, indicating a significant ownership stake in Contineum Therapeutics, Inc. The filing reveals that Johnson & Johnson Innovation-JJDC, Inc. beneficially owns 1,979,173 shares of Contineum Therapeutics' Class A Common Stock, which represents 10.7% of the class. This ownership level was based on the number of shares outstanding after Contineum Therapeutics' initial public offering on April 9, 2024. The filing was made pursuant to Rule 13d-1(c) and indicates that the shares are not held with the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect.
Johnson & Johnson, through its subsidiary Johnson & Johnson Innovation-JJDC, Inc., has filed a Schedule 13G with the Securities and Exchange Commission on April 10, 2024, indicating a significant ownership stake in Contineum Therapeutics, Inc. The filing reveals that Johnson & Johnson Innovation-JJDC, Inc. beneficially owns 1,979,173 shares of Contineum Therapeutics' Class A Common Stock, which represents 10.7% of the class. This ownership level was based on the number of shares outstanding after Contineum Therapeutics' initial public offering on April 9, 2024. The filing was made pursuant to Rule 13d-1(c) and indicates that the shares are not held with the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having such purpose or effect.
強生通過其子公司強生創新-JJDC, Inc. 於2024年4月10日向美國證券交易委員會提交了附表13G，表明Contineum Therapeutics, Inc.擁有大量所有權。該文件顯示，強生創新-JJDC, Inc.實益擁有Contineum Therapeutics的1,979,173股A類普通股，佔該類別的10.7％。該所有權水平基於Contineum Therapeutics於2024年4月9日首次公開募股後的已發行股票數量。該申報是根據第13d-1（c）條提交的，表明持有股份的目的不是爲了改變或影響發行人的控制權，也不是與具有此類目的或效力的任何交易有關。
強生通過其子公司強生創新-JJDC, Inc. 於2024年4月10日向美國證券交易委員會提交了附表13G，表明Contineum Therapeutics, Inc.擁有大量所有權。該文件顯示，強生創新-JJDC, Inc.實益擁有Contineum Therapeutics的1,979,173股A類普通股，佔該類別的10.7％。該所有權水平基於Contineum Therapeutics於2024年4月9日首次公開募股後的已發行股票數量。該申報是根據第13d-1（c）條提交的，表明持有股份的目的不是爲了改變或影響發行人的控制權，也不是與具有此類目的或效力的任何交易有關。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息